How Deciem Built a Science-First Skincare Brand: Inside The Ordinary’s Evidence-Based Model

Table of Contents

  1. Key Highlights:
  2. Introduction
  3. The origins of an ingredient-focused brand
  4. Building scientific infrastructure: why in-house labs matter
  5. Clinical research pillars and the anatomy of meaningful testing
  6. From ingredient audit to shelf: the product development workflow
  7. An illustrative case study: developing an azelaic acid serum
  8. Balancing innovation, safety, and the consumer experience
  9. The wider industry response: credibility as a commodity
  10. Business strategy: accessibility, pricing, and corporate backing
  11. Emerging technologies and next-generation ingredients
  12. How to read skincare claims: a consumer guide
  13. Risks and limits of evidence-based marketing
  14. Practical implications for formulators and clinicians
  15. Looking ahead: what evidence-based beauty will look like in five years
  16. FAQ

Key Highlights:

  • Deciem has centralized scientific capability—five in‑house labs and more than 150 specialists—to anchor product development in rigorous clinical evidence.
  • The Ordinary popularized ingredient-led, transparent formulations (examples: hyaluronic acid, azelaic acid, niacinamide) and continues to evolve by combining method development, internal and external studies, and supplier audits.
  • Scientific rigour is enabling broader creativity across beauty: credible data drives consumer trust, guides innovation, and preserves accessibility through disciplined formulation and testing.

Introduction

Consumers now expect more than promises. Skincare shoppers want measurable outcomes supported by data. That shift has reshaped product development across the beauty industry and turned scientific validation into a competitive necessity. Few brands have crystallized that change as visibly as The Ordinary. Launched by Deciem with a deliberately clinical aesthetic and an ingredient-first philosophy, The Ordinary foregrounded transparency: single-actives, clear concentrations, and straightforward packaging pulled the curtain back on formulation and invited consumers to become informed participants in their routines.

Deciem began with founders Brandon Truaxe and Nicole Kilner aiming to create multiple brands founded on science. Growth accelerated after a phased investment and eventual acquisition by Estée Lauder Companies, which enabled broader reach and resources. Today Deciem operates with a more expansive scientific backbone: five labs housed under one roof and a clinical team exceeding 150 specialists. That infrastructure supports a model where robust internal science meets external collaboration, and where claim substantiation guides both product design and consumer communication.

Carla O’Connor, Deciem’s Director of Global Clinical Research, has described the company's approach as combining clinical pillars, method development, and both internal and external studies to produce “robust, substantiated claims.” That formula explains how a brand once synonymous with stripped-back serums now navigates next-generation actives, multi-active formulations, and sophisticated clinical testing—without losing sight of accessibility.

The sections that follow unpack how Deciem has built and operationalized a science-first model, what it means for formulation and marketing, how the broader industry is responding, and how consumers can read efficacy claims with an informed eye.

The origins of an ingredient-focused brand

The Ordinary arrived at a moment when mainstream beauty often masked complexity in marketing. Rather than lean into aspirational storytelling, The Ordinary emphasized the ingredients themselves—hyaluronic acid, niacinamide, retinoids, azelaic acid—often listing concentrations directly on labels. Presentation borrowed from pharmacy aesthetics: clear bottles, minimal extraneous branding, and language that invited comparison with pharmaceutical-grade actives.

This approach did three things at once:

  • It educated consumers about what each ingredient does.
  • It simplified purchasing decisions for people seeking targeted outcomes, such as hydration, sebum regulation, or acne control.
  • It positioned price transparency as a virtue; accessible pricing undercut the idea that efficacy required premium markups.

Founders Brandon Truaxe and Nicole Kilner set out with a vision to build multiple brands under a broader parent whose core value was scientific integrity. That ambition produced a company culture oriented to testing, evidence, and supplier transparency rather than trend-chasing alone. The Ordinary’s early success hinged on meeting unmet demand: shoppers wanted straightforward, affordable actives they could trust.

That early positioning forced competitors to respond. Ingredient transparency and evidence-backed communication migrated from a niche to a mainstream expectation. Brands that previously relied on story-driven marketing began to publish ingredient lists, clinical summaries, or third-party test results. The Ordinary’s influence thus extends beyond sales figures; it helped shift the baseline of consumer expectations.

Building scientific infrastructure: why in-house labs matter

Scaling from an ingredient-led startup to a global player required different infrastructure. Deciem invested heavily in centralized scientific capability: research and development (R&D), clinical research, microbiology, stability, and analytical labs under one roof. Staffing grew to more than 150 specialists across disciplines—formulators, clinical scientists, microbiologists, analytical chemists, statisticians, and regulatory experts.

Centralizing labs and talent offers practical advantages:

  • Shorter iteration cycles. Immediate access to analytical and stability data speeds formulation refinements and reduces time-to-market for validated products.
  • Cross-disciplinary collaboration. Proximity means formulators and clinical teams can co-design studies and refine endpoints that matter both scientifically and commercially.
  • Consistent quality control. In-house analytical capacity enables rapid confirmation of active concentrations, impurity profiles, and batch-to-batch consistency.
  • Faster troubleshooting. Microbial contamination, formulation instability, or unexpected interactions can be diagnosed and addressed without the delay of external shipping and scheduling.

Each lab plays a specific role in the development lifecycle:

  • R&D lab: Concept to prototype. Formulators test excipients, textures, pH ranges, and compatibility of actives. This is where feel, absorption, and aesthetic attributes are balanced with functional performance.
  • Clinical research lab: Study design and execution. Teams define meaningful endpoints, recruit participants, perform in-clinic assessments, and manage consumer perception studies.
  • Microbiology lab: Preservation and safety assessment. Scientists test for preservative efficacy, contamination risks, and microbiome compatibility when relevant.
  • Stability lab: Long-term and accelerated stability testing. Products undergo temperature and humidity stress testing to validate shelf life and packaging performance.
  • Analytical lab: Assays and quantitation. High-performance liquid chromatography (HPLC), mass spectrometry, and other techniques confirm active concentrations and detect degradation products.

This integrated structure reduces dependency on external testing providers for routine work, while allowing Deciem to partner externally for specialized assays or independent verification when needed. The goal is speed without sacrificing the impartiality that independent collaboration brings.

Clinical research pillars and the anatomy of meaningful testing

Deciem frames its clinical research around several pillars that determine whether findings will translate into credible consumer claims. These pillars influence which studies get prioritized and how teams design methods to deliver clear answers.

Key considerations include:

  • Relevance of clinical endpoints. Outcomes must reflect perceivable benefits—reduced wrinkle depth, improved hydration, fewer inflammatory lesions—rather than obscure biochemical markers that lack direct consumer meaning.
  • Appropriate study populations. Trials must include participants whose baseline characteristics make change plausible, and they should reflect demographic diversity when claims are intended for broad markets.
  • Robust controls. Placebo or vehicle-controlled designs, split-face protocols, and randomized controlled trials minimize bias and improve interpretability.
  • Objective measurements. Instrumental methods—biophysical tools measuring transepidermal water loss, corneometry for hydration, colorimetry for erythema—complement investigator and consumer-reported outcomes.
  • Statistical rigour. Proper powering and pre-specified analyses prevent over-interpretation of small or non-reproducible effects.
  • Repeatability and external verification. Internal findings gain credibility when supported by external partners or replicated across cohorts.

Clinical teams lead method development to ensure tests probe the right questions. For example, a product designed to reduce hyperpigmentation will require different imaging modalities and scoring than one targeting skin barrier function. That clarity of purpose determines resource allocation: a well-designed—but narrowly focused—study will produce more actionable evidence than a broad, poorly powered trial.

Testing types commonly used across the industry and at Deciem include:

  • In vitro assays: Cellular or biochemical tests to screen active mechanisms—antioxidant capacity, enzyme inhibition, collagen synthesis markers.
  • Ex vivo studies: Human skin explants used to assess penetration, local responses, or metabolic transformations without immediate human trials.
  • Instrumental measurements: Objective devices quantify hydration, sebum, elasticity, and pigmentation changes.
  • Consumer perception studies: Questionnaires capture real-world satisfaction, tolerability, and perceived change, often essential for marketing claims.
  • Randomized controlled clinical trials: Gold-standard human studies that support stronger claims when designed and executed properly.

Combining these approaches creates a weight-of-evidence model. Early screening narrows candidates; analytical and safety testing confirm formulation integrity; clinical assessment demonstrates real-world performance.

From ingredient audit to shelf: the product development workflow

Deciem's development process begins long before a serum bottle is filled. Every ingredient undergoes an internal audit that traces provenance, scientific literature, supplier data, and potential interactions. This audit identifies known efficacy, safety signals, and gaps in the evidence base.

Supplier relationships play a major role. Trusted vendors provide technical dossiers, stability data, impurant profiles, and manufacturing controls. Deciem’s approach blends these external data streams with its own tests to decide if an ingredient merits further investment.

A typical workflow looks like this:

  1. Ingredient discovery and vetting
    • Literature review and supplier dossier appraisal.
    • In vitro screening for mechanism-of-action and cytotoxicity.
    • Pricing and supply chain assessment to maintain accessibility.
  2. Prototype formulation
    • Early formulation attempts assess solubility, pH, and compatibility.
    • Preservation and microbiology screens ensure safety.
    • Sensory and aesthetic testing ensures consumer acceptability.
  3. Analytical and stability testing
    • Quantitative assays validate active concentration under intended storage conditions.
    • Accelerated and real-time stability studies evaluate degradation and packaging interaction.
  4. Method development and pilot clinical testing
    • Selection of endpoints, instruments, and scoring systems.
    • Pilot cohorts test tolerability and provide preliminary efficacy signals.
  5. Pivotal clinical studies and consumer perception trials
    • Larger, controlled studies quantify effect size and statistical significance.
    • Perception studies measure consumer-reported benefit and tolerability.
  6. Claim substantiation and regulatory review
    • Legal and regulatory teams align claim language with evidence and jurisdictional requirements.
    • Marketing materials are drafted to reflect substantiated benefits.
  7. Launch and post-market surveillance
    • Real-world feedback and adverse event monitoring inform reformulations or additional studies.
    • Shelf-life monitoring continues to ensure long-term product integrity.

This sequence insists on patience: meaningful claims require investment in reliable evidence. The approach contrasts with fly-by-night launches that rely on influencer hype or preliminary assays to support broad claims.

An illustrative case study: developing an azelaic acid serum

Carla O’Connor referenced a case study in which Deciem combined ingredient discovery, formulation science, and clinical testing. The company’s public repertoire includes well-known actives such as azelaic acid, hyaluronic acid, and niacinamide. Below is an illustrative, generalized walkthrough inspired by Deciem’s described model; it demonstrates how a brand transforms scientific rationale into substantiated consumer claims.

Step 1: Rationale and initial screening

  • Azelaic acid is known for anti-inflammatory, antimicrobial, and depigmenting properties. Supplier dossiers and literature indicate plausible efficacy for mild-to-moderate inflammatory lesions and post-inflammatory hyperpigmentation.
  • Early in vitro assays assess keratinocyte response, melanin synthesis inhibition, and antimicrobial activity against Cutibacterium acnes.

Step 2: Formulation challenges and solutions

  • Azelaic acid has limited solubility. Formulators evaluate vehicles, particle size, and pH adjustment to ensure stability and skin bioavailability.
  • Preservation testing confirms compatibility with the chosen base, and microbiology screens validate preservative efficacy.

Step 3: Analytical and stability confirmation

  • Analytical chemistry establishes a validated assay to quantitate azelaic acid concentration and identify potential degradation products.
  • Accelerated stability tests reveal whether the active degrades at common temperature extremes or interacts with packaging.

Step 4: Pilot clinical proof-of-concept

  • A small randomized, split-face or vehicle-controlled pilot measures tolerability and preliminary efficacy over 8–12 weeks.
  • Objective measures include lesion counts, erythema scoring, and high-resolution imaging for pigmentation; consumer questionnaires capture perceived improvement and irritation.

Step 5: Pivotal randomized controlled trial

  • Powered to detect a clinically meaningful reduction in lesion counts and an improvement in pigmentation indices.
  • Secondary endpoints assess tolerability, erythema reduction, and consumer satisfaction.
  • Statistically significant improvements over vehicle allow for clear claim language reflecting the measured outcomes.

Step 6: Post-launch monitoring

  • Real-world surveillance tracks adverse events and broader population responses.
  • If necessary, additional studies explore usage patterns, combination with other actives, or long-term effects.

This process illustrates how scientific reasoning intersects with pragmatic formulation choices. A promising mechanism is only valuable when paired with a vehicle that delivers the active safely and consistently and a study that measures outcomes people care about.

Balancing innovation, safety, and the consumer experience

Some industry voices worry that rigorous demands for evidence might dampen creativity or remove the "fun" from beauty. Deciem’s experience suggests the opposite: science unlocks new forms of creativity by imposing constraints that force innovation to be purposeful.

Constraints can stimulate novel solutions:

  • Texture and delivery innovation. Limited solubility or irritation risk prompts research into liposomal carriers, prodrugs, or encapsulation techniques that preserve efficacy while improving sensory experience.
  • Multi-active harmonization. Combining actives requires creative formulation to avoid antagonistic interactions while preserving potency. That challenge yields novel emulsions, stabilizing excipients, and sequencing recommendations.
  • Packaging engineering. Light- and air-sensitive actives inspire packaging that protects integrity—airless pumps, opaque tubes, or amber glass—while enabling elegant consumer design.

These advancements permit brands to deliver products that are both pleasurable to use and effective. Scientific rigour is not an aesthetic straitjacket; it creates guardrails that guide R&D toward solutions with demonstrable benefits.

Safety remains non-negotiable. Clinical teams perform irritation and sensitization testing, and microbiologists verify preservative systems. That diligence prevents costly recalls and preserves consumer trust, which is more valuable than short-term novelty.

The wider industry response: credibility as a commodity

The Ordinary’s success and Deciem’s investments illustrate a broader industry trend: consumers reward transparency and measurable outcomes. That shift pressures brands to demonstrate efficacy and increases scrutiny from regulators, retailers, and third-party evaluators.

Consequences for the industry include:

  • Greater investment in proof-of-concept and pivotal studies across price tiers.
  • Growth in third-party verification services, ISO-accredited labs, and independent clinical sites.
  • A rise in evidence-focused marketing that clarifies limitations and endpoints—claims that specify "clinically proven to reduce wrinkle depth by X% in Y weeks" rather than vague promises.

Regulatory frameworks vary by market, but authorities are increasingly attentive to unsubstantiated claims. Companies that pair marketing language with verifiable data reduce regulatory risk and strengthen retailer partnerships, especially in healthcare-adjacent distribution channels like pharmacies.

Not every claim needs a randomized controlled trial. The decision depends on the claim's audacity, the size of the target market, and the risk profile of the ingredient. Lightweight perception studies can suffice for low-impact claims, while transformational or therapeutic claims demand more substantial evidence.

Transparency about study design and outcomes matters. Publishing methodological summaries—sample size, endpoints, control conditions—builds consumer trust. When brands disclose limitations and the precise scope of claims, they invite informed comparison rather than marketing-driven confusion.

Business strategy: accessibility, pricing, and corporate backing

Deciem’s founding proposition—effective ingredients at reasonable prices—remains central. Building internal labs and clinical teams is expensive, but centralized capability can generate economies of scale over a portfolio of products. Accurate analytical methods, faster iteration cycles, and internal safety testing reduce per-product external testing spend over time.

Estée Lauder Companies’ phased investment and eventual acquisition provided capital and distribution advantages without necessarily diluting Deciem’s scientific ethos. Greater resources facilitated larger clinical programs, expanded lab infrastructure, and broader global reach. Corporate backing also brings governance, regulatory resources, and access to specialized contract research organizations when external verification is needed.

Balancing accessibility with rigorous science requires cost discipline. Choices include:

  • Prioritizing evidence for flagship or claim-driving SKUs while using lightweight studies for supporting ranges.
  • Leveraging pooled infrastructure across brands to amortize lab costs.
  • Negotiating supplier partnerships for shared research to reduce duplicate spending.

The result is an ability to maintain price competitiveness while upholding evidence standards. Consumers benefit from options that are both affordable and substantiated.

Emerging technologies and next-generation ingredients

Deciem’s model includes exploring next-generation actives and technologies—areas that demand new methods and novel clinical endpoints. Several trends are gaining traction across the industry:

  • Biomarker-driven personalization. Molecular markers and consumer phenotyping guide individualized regimens and targeted claims. This approach requires quantitative assays and well-defined biomarker–outcome correlations.
  • Microbiome-aware formulations. Products that maintain or modulate the skin microbiome need specialized culture methods, sequencing, and interpretation frameworks that translate microbial shifts into clinical meaning.
  • Encapsulation and targeted delivery. Nanocarriers and encapsulation enhance penetration and stability but raise safety and regulatory questions that require specific testing.
  • Data-driven formulation. Machine learning can accelerate screening and predict interactions. Models need robust datasets and human validation to move from prediction to product.
  • Sustainability metrics. Lifecycle analyses and green chemistry approaches intersect with efficacy demands, forcing formulators to reconcile lower-impact ingredients with comparable performance.

Adoption of these technologies requires a parallel investment in methodological capability. New endpoints, such as microbiome diversity metrics or biomarker expression changes, must be validated for clinical relevance and consumer interpretation.

How to read skincare claims: a consumer guide

Consumers face a crowded field of claims. Knowing how to evaluate evidence helps separate genuine progress from marketing spin.

Look for the following features in claim substantiation:

  • Clear endpoints. Prefer claims tied to measurable outcomes—hydration, lesion count, pigmentation index—over vague assertions like “brightens” without context.
  • Study details. Credible brands disclose study population size, duration, and control conditions. Small sample sizes or short-term tests have limited interpretability.
  • Objective measures plus perception data. Instrumental data paired with consumer feedback provides a fuller picture.
  • Independent verification or peer review. External studies or publication in scientific journals add credibility.
  • Realistic timelines. Many active ingredients require weeks to demonstrate effects. Claims promising overnight transformation often reflect marketing rather than data.
  • Full ingredient transparency. Knowing active concentrations and complementary ingredients reduces reliance on anecdote.

Consumers with sensitive skin should seek products with well-documented tolerability data and clear instructions for introduction (e.g., frequency, layering, sunscreen requirement).

Risks and limits of evidence-based marketing

Evidence-based approaches reduce ambiguity, but they are not infallible. Potential pitfalls include:

  • Overgeneralization. A study in a narrow demographic does not guarantee identical results in other populations.
  • Misaligned endpoints. Measured outcomes may not align with what consumers care about; for example, a reduction in a cellular marker may not translate to visible improvement.
  • Confounding variables. Concurrent use of other products or lifestyle factors can influence results if not controlled in trials.
  • Statistical vs. clinical significance. A statistically significant change may be too small to matter practically.

Brands must present evidence responsibly and avoid implying broader efficacy than demonstrated. Consumers benefit from brands that clearly define the scope and limitations of their claims.

Practical implications for formulators and clinicians

Formulators must balance several sometimes-competing demands: potency, stability, tolerability, sensory experience, and cost. Clinical teams help by defining endpoints that matter to patients and consumers and by guiding study designs that produce data meaningful to regulatory and marketing stakeholders.

Clinicians advising patients should ask for study details when recommending products. Useful questions include:

  • Was the study randomized and controlled?
  • How large was the study population, and what were the inclusion criteria?
  • Which endpoints were measured and by what instruments?
  • What were the primary safety findings?

Clinicians who understand the evidence landscape can better tailor regimens and anticipate likely outcomes.

Looking ahead: what evidence-based beauty will look like in five years

Trends suggest continued maturation of evidence-based beauty. Expect wider adoption of standardized reporting for clinical studies, more cross-industry collaboration on methods, and growth in tools that make study data understandable to consumers.

Personalization will accelerate as brands pair validated ingredients with biomarkers and consumer phenotypes. The industry will demand interoperable data standards so that analytical results, microbiome profiles, and clinical outcomes can be compared meaningfully.

Regulatory scrutiny will increase, particularly where claims approximate therapeutic effects. Brands will need clearer boundaries between cosmetic benefit and medical claims. This will incentivize deeper investment in robust evidence for higher-stakes claims and measured, transparent language for everyday products.

Sustainability and efficacy will converge. Consumers will expect proof that lower-impact ingredients can match performance, pushing formulation science to reconcile environmental goals with measurable results.

Finally, the battle for consumer trust will hinge less on short-term marketing and more on sustained evidence and transparent communication. Brands that combine credible science, clear messaging, and accessible pricing will occupy the strongest position.

FAQ

Q: What types of studies does Deciem run to substantiate claims? A: Deciem employs a mix of in vitro and ex vivo screening, analytical validation, microbiology and stability testing, consumer perception studies, and randomized controlled clinical trials. Method development ensures endpoints are meaningful, and studies use appropriate controls and objective instrumentation alongside consumer-reported outcomes.

Q: Why does Deciem keep multiple labs in-house? A: Centralized labs shorten iteration cycles, enable close collaboration between formulation and clinical teams, and maintain consistent quality control. In-house capability accelerates troubleshooting and ensures batch-to-batch verification, although Deciem still collaborates externally for specialized assays and independent verification where appropriate.

Q: How does the company decide which ingredients to pursue? A: Every ingredient undergoes an internal audit that includes a literature review, supplier dossiers, and early screening assays. Considerations include mechanistic rationale, safety profile, supply chain reliability, cost (to maintain accessibility), and feasibility of developing a vehicle that delivers the active effectively.

Q: Do these scientific processes make products more expensive? A: Building scientific infrastructure requires investment, but centralized labs and cross-portfolio testing can create economies of scale. Deciem has sought to preserve accessible pricing by prioritizing evidence for claim-driving products and leveraging portfolio-level efficiencies.

Q: Can scientific rigour limit creativity in formulation? A: Constraints arising from safety, stability, and efficacy demand creative solutions rather than eliminate them. Challenges like solubility or irritation inspire innovations in delivery systems, encapsulation, packaging, and texture engineering that enhance consumer experience.

Q: How should consumers evaluate efficacy claims? A: Look for clear endpoints, study size and duration, control conditions, objective measurements, and transparency in methodology. Beware of small pilot studies being presented as definitive proof. Independent verification and publication strengthen credibility.

Q: Are the clinical studies published in journals? A: Brands vary in publication practices. Some publish detailed methodological summaries or peer-reviewed papers for major claims, while others provide study summaries and data in product dossiers or on corporate websites. Independent or peer-reviewed publication adds credibility but is not the only indicator of robustness.

Q: What role do suppliers and external partners play? A: Suppliers provide technical dossiers, manufacturing details, and sometimes co-funding for early research. Deciem integrates supplier data with internal testing and retains the ability to commission independent labs for specialized analyses.

Q: How do multi-active formulations affect testing? A: Combining actives creates complexity—interactions can affect stability, absorption, and tolerability. Method development must evaluate combined effects, and clinical endpoints may need to capture synergistic or antagonistic outcomes. This often requires additional stability and compatibility testing.

Q: How will evidence-based skincare evolve? A: Expect greater standardization of study reporting, more biomarker-driven personalization, expanded microbiome assays, and stronger links between sustainability metrics and efficacy. Brands that transparently align claims with data will gain consumer trust.

Q: If a product shows a biomarker change, does that mean visible results? A: Not necessarily. Biomarker shifts indicate biological activity but may not translate into perceivable change within the study timeframe or for all consumers. Clinical endpoints that capture visible outcomes and consumer perception complement biomarker data for a fuller picture.

Q: What should clinicians ask when recommending products? A: Request study details: design, population, endpoints, duration, and safety findings. Ask whether studies included diverse skin types and how results generalize to your patient’s circumstances.

Q: How should brands communicate limits of evidence without undermining trust? A: Brands should present precise language, specify study contexts, and avoid extrapolating beyond tested conditions. Being upfront about limitations fosters credibility. Clear, non-technical summaries of study results help consumers make informed choices.

Q: Can evidence-based skincare still be fun? A: Yes. Scientific constraints encourage design ingenuity in texture, scent-free options, packaging, and formulation engineering. Effective products that also deliver enjoyable experiences are increasingly achievable.

Q: Where can consumers find more information about a product’s studies? A: Company websites often host study summaries and methodology notes. Independent journals, clinical trial registries, and consumer information sites can provide additional context. For clinical-grade products, pharmacy-led resources may offer verified summaries.

Q: Does an in-house lab mean results are biased? A: In-house labs enable rapid testing, but credible companies combine internal research with external collaborations and independent verification when appropriate. Transparency about methods and external replication reduces bias concerns.

Q: What claims should prompt caution? A: Promise of immediate, dramatic changes, or vague language without study context merit skepticism. Also be wary when the only supporting evidence is a single small pilot trial or in vitro data presented as proof of clinical benefit.

Q: How does regulatory oversight affect claims? A: Regulations differ by market. Claims that imply disease treatment can trigger medical product regulation; cosmetic claims are allowed more latitude but still must be substantiated and not misleading. Brands must ensure claim language complies with local rules.

Q: How do preservation and microbiology testing affect product safety? A: Preservation systems are essential to prevent microbial contamination. Microbiology labs test preservative efficacy, shelf-life safety, and compatibility with packaging and product use conditions to ensure consumer safety over time.

Q: Will more brands follow Deciem’s model? A: The trend toward evidence-based claims is growing across price tiers. Brands that can effectively combine scientific rigour with accessible pricing and clear communication will likely capture market share as consumer expectations rise.

This article examines how a company rooted in transparency and ingredient-focused design built institutional scientific capability to validate and expand its portfolio. The model balances accessible pricing with rigorous method development, analytical validation, and consumer-centered clinical research—an approach reshaping how skincare effectiveness is proven and communicated.